FACTORS INFLUENCING PLASMA-LEVEL DOSE RATIOS OF CARBAMAZEPINE AND ITS MAJOR METABOLITES IN EPILEPTIC CHILDREN

被引:19
作者
HARTLEY, R
LUCOCK, MD
NG, PC
FORSYTHE, WI
MCLAIN, B
BOWMER, CJ
机构
[1] UNIV LEEDS,DEPT PHARMACOL,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND
[2] UNIV LEEDS,DEPT PAEDIAT & CHILD HLTH,PAEDIAT RES UNIT,LEEDS LS2 9JT,W YORKSHIRE,ENGLAND
关键词
Carbamazepine; Children; Drug monitoring; Major metab-olites; Monotherapy; Plasma level/dose ratios;
D O I
10.1097/00007691-199009000-00006
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The relationship between daily dose and plasma concentrations of carbamazepine (CBZ), CBZ-10,11-epoxide (CBZ-EP), and 10,11-dihydro-10,11 -trans-dihydroxy-CBZ (CBZ-DIOL) was investigatedin 21 children aged 7–16 years who received CBZ monotherapy, twice daily in equally divided doses. Significant linear correlations between CBZ dose and plasma levels were obtained for CBZ and its metabolites (p < 0.01). In addition, the effects of daily dose and patients' age on the plasma level/dose ratios for CBZ, CBZ-EP, and CBZ-DIOL were evaluated. A significantnegative correlation was observed between the daily dose of CBZand the CBZ plasma level/dose ratio (p < 0.01). By contrast, plasma level/dose ratios for CBZ-EP and CBZ-DIOL were independent of dose (p > 0.1). On the basis of these observations,we consider that the decrease in CBZ plasma level/dose ratio withincreasing CBZ dose appears to be due to dose-dependent metabolicclearance of CBZ. The influence of age on plasma level/doseratiosfor CBZ and its metabolites was not significant (p > 0.05). However, there was considerable interdose and diurnal variation in the plasma level/dose ratios, particularly for CBZ (28–41%); this must be taken into account when making dose adjustments based on plasma level/dose ratios. © 1990 Raven Press, Ltd., New York.
引用
收藏
页码:438 / 444
页数:7
相关论文
共 32 条
[1]   POOR CORRELATION BETWEEN SINGLE-DOSE DATA AND STEADY-STATE KINETICS FOR PHENOBARBITONE, PRIMIDONE, CARBAMAZEPINE AND SODIUM VALPROATE IN CHILDREN DURING MONOTHERAPY - POSSIBLE REASONS FOR THE LACK OF CORRELATION [J].
ARMIJO, JA ;
HERRANZ, JL ;
ARTEAGA, R ;
VALIENTE, R .
CLINICAL PHARMACOKINETICS, 1986, 11 (04) :323-335
[2]   CARBAMAZEPINE PLASMA-LEVELS IN CHILDREN AND ADULTS - INFLUENCE OF AGE, DOSE, AND ASSOCIATED THERAPY [J].
BATTINO, D ;
BOSSI, L ;
CROCI, D ;
FRANCESCHETTI, S ;
GOMENI, C ;
MOISE, A ;
VITALI, A .
THERAPEUTIC DRUG MONITORING, 1980, 2 (04) :315-322
[3]   PHARMACOKINETICS - TIME-DEPENDENT CHANGES - AUTOINDUCTION OF CARBAMAZEPINE EPOXIDATION [J].
BERTILSSON, L ;
TOMSON, T ;
TYBRING, G .
JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 26 (06) :459-462
[4]   CLINICAL PHARMACOKINETICS OF CARBAMAZEPINE [J].
BERTILSSON, L .
CLINICAL PHARMACOKINETICS, 1978, 3 (02) :128-143
[5]  
BOURGEOIS BFD, 1984, THER DRUG MONIT, V6, P259, DOI 10.1097/00007691-198409000-00001
[6]  
COTTER L M, 1975, Proceedings of the Australian Association of Neurologists, V12, P123
[7]   PHARMACOKINETICS OF CARBAMAZEPINE [J].
COTTER, LM ;
EADIE, MJ ;
HOOPER, WD ;
LANDER, CM ;
SMITH, GA ;
TYRER, JH .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 12 (06) :451-456
[8]  
EADIE MJ, 1980, ANTICONVULSANT THERA, P132
[9]   CARBAMAZEPINE METABOLISM IN MAN INDUCTION AND PHARMACOGENETIC ASPECTS [J].
EICHELBAUM, M ;
TOMSON, T ;
TYBRING, G ;
BERTILSSON, L .
CLINICAL PHARMACOKINETICS, 1985, 10 (01) :80-90
[10]   FACTORS INFLUENCING SIMULTANEOUS CONCENTRATIONS OF TOTAL AND FREE CARBAMAZEPINE AND CARBAMAZEPINE-10, 11-EPOXIDE IN SERUM OF CHILDREN WITH EPILEPSY [J].
ELYAS, AA ;
PATSALOS, PN ;
AGBATO, OA ;
BRETT, EM ;
LASCELLES, PT .
THERAPEUTIC DRUG MONITORING, 1986, 8 (03) :288-292